Montenero Annibale S, Bruno Nicola, Antonelli Andrea, Mangiameli Daniele, Barbieri Luca, Andrew Peter, Murphy Olive, O'Connor Stephen, Zumbo Francesco
Cardiology Department and Arrhythmia Center of Policlinico MultiMedica, Sesto S.Giovanni, Milan, Italy.
J Am Coll Cardiol. 2005 Feb 15;45(4):573-80. doi: 10.1016/j.jacc.2004.10.059.
We investigated the long-term efficacy of cryo ablation for treatment of atrial flutter.
To our knowledge, no study has assessed the long-term efficacy of cryo ablation by assessing both symptom and conduction recurrence.
A total of 45 consecutive patients with symptomatic atrial flutter were ablated with a 7-F, 6-mm-tip, quadripolar cryo catheter (Freezor Xtra, CryoCath Technologies Inc., Kirkland, Canada). Electrophysiologic studies (EPS) were performed with diagnostic catheters. Cryo ablation was at -75 degrees C for 4 min, beginning at the inferior rim of the coronary sinus os and creating a posterior line to the Eustachian ridge. Safety, bi-directional isthmus block at intervention, and recurrence at three, six, and nine months post procedure were assessed.
There were no adverse events reported. All patients were free of discomfort on cryo energy delivery. The acute success rate at intervention was 87%. Follow-up data from 39 acutely successful patients showed 27 (69%) without conduction recurrence on repeat EPS at three months, and none (0%) had symptom recurrence documented by Holter monitoring, electrocardiogram, and/or patient diary records at three, six, and nine months follow-up.
Our experience with a new 7-F, 6-mm-tip, quadripolar cryo catheter yielded a fairly high success rate at intervention, an excellent safety profile, and a good chronic success rate in terms of symptom recurrence. However, further monitoring is necessary to determine whether all asymptomatic patients continue to remain free of symptoms, given the small pool of patients demonstrated to have conduction recurrence.
我们研究了冷冻消融治疗心房扑动的长期疗效。
据我们所知,尚无研究通过评估症状和传导复发情况来评估冷冻消融的长期疗效。
连续45例有症状的心房扑动患者采用7F、6mm尖端的四极冷冻导管(Freezor Xtra,CryoCath Technologies Inc.,加拿大柯克兰)进行消融。使用诊断导管进行电生理研究(EPS)。冷冻消融在-75℃下进行4分钟,从冠状窦口下缘开始,向欧氏嵴形成一条后线。评估安全性、干预时的双向峡部阻滞以及术后3个月、6个月和9个月的复发情况。
未报告不良事件。所有患者在冷冻能量输送过程中均无不适。干预时的急性成功率为87%。39例急性成功患者的随访数据显示,3个月时重复EPS检查27例(69%)无传导复发,3个月、6个月和9个月随访时,动态心电图监测、心电图和/或患者日记记录均未记录到症状复发(0%)。
我们使用新型7F、6mm尖端四极冷冻导管的经验显示,干预时成功率较高,安全性良好,症状复发方面的慢性成功率也较好。然而,鉴于仅有少量患者出现传导复发,有必要进一步监测以确定所有无症状患者是否继续无症状。